

# NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

## HEALTH TECHNOLOGY APPRAISAL PROGRAMME

### Equality impact assessment – Guidance development

#### STA Lorlatinib for untreated ALK-positive advanced non-small-cell lung cancer [ID6434]

The impact on equality has been assessed during this appraisal according to the principles of the NICE equality scheme.

#### Consultation

- |                                      |  |
|--------------------------------------|--|
| 1.                                   | Have the potential equality issues identified during the scoping process been addressed by the committee, and, if so, how? |
| No issues identified during scoping. |  |

- |   |   |
|---|---|
| 2.  | Have any other potential equality issues been raised in the submissions, expert statements or academic report, and, if so, how has the committee addressed these? |
| <p>The company highlighted that some underserved communities and ethnic or socioeconomic groups have later diagnosis and worse outcomes, and that this likely includes those with ALK-positive advanced NSCLC. But because its recommendation does not restrict access to treatment for some people over others, the committee agreed this was not a potential equalities issue that it could address.</p> <p>The patient organisations also noted that there is inequitable access to lorlatinib across the UK, as it is available in Scotland. It noted that geographic location is not a protected characteristic.</p> <p>The committee concluded that the recommendations would not have a different effect on people protected by equality legislation than on the wider population.</p> |   |

3.	Have any other potential equality issues been identified by the committee, and, if so, how has the committee addressed these?
No other issues.	

  

4.	Do the preliminary recommendations make it more difficult in practice for a specific group to access the technology compared with other groups? If so, what are the barriers to, or difficulties with, access for the specific group?
No.	

  

5.	Is there potential for the preliminary recommendations to have an adverse impact on people with disabilities because of something that is a consequence of the disability?
No.	

  

6.	Are there any recommendations or explanations that the committee could make to remove or alleviate barriers to, or difficulties with, access identified in questions 4 or 5, or otherwise fulfil NICE's obligations to promote equality?
Not applicable.	

  

7.	Have the committee's considerations of equality issues been described in the draft guidance, and, if so, where?
Yes, section 3.22.	

**Approved by Associate Director (name):** Ian Watson

**Date:** 01 April 2025